Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N. Raymond E, et al. Among authors: cubillo a. Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10. Neuroendocrinology. 2018. PMID: 29991024
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P. Van Cutsem E, et al. Among authors: cubillo a. Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9. Int J Cancer. 2018. PMID: 29756206 Free article. Clinical Trial.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Regan MM, et al. Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20. Lancet Oncol. 2011. PMID: 22018631 Free PMC article. Clinical Trial.
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer.
Rodríguez-Pascual J, Sha P, García-García E, Rajeshkumar NV, De Vicente E, Quijano Y, Cubillo A, Angulo B, Hernando O, Hidalgo M. Rodríguez-Pascual J, et al. Among authors: cubillo a. Invest New Drugs. 2013 Feb;31(1):14-9. doi: 10.1007/s10637-012-9822-x. Epub 2012 Jun 7. Invest New Drugs. 2013. PMID: 22669334 Clinical Trial.
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Among authors: cubillo a. Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1. Br J Cancer. 2013. PMID: 23907428 Free PMC article.
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Among authors: cubillo a. Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. Br J Cancer. 2014. PMID: 24642623 Free PMC article. No abstract available.
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A, Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E. Paz-Ares L, et al. Among authors: cubillo a. Invest New Drugs. 2017 Apr;35(2):198-206. doi: 10.1007/s10637-016-0410-3. Epub 2016 Nov 21. Invest New Drugs. 2017. PMID: 27873130 Free article. Clinical Trial.
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Pelzer U, et al. Among authors: cubillo a. Br J Cancer. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67. Epub 2017 Mar 28. Br J Cancer. 2017. PMID: 28350787 Free PMC article. Clinical Trial.
88 results